EP0531342A1 - Cyclized and linear therapeutic peptides - Google Patents

Cyclized and linear therapeutic peptides

Info

Publication number
EP0531342A1
EP0531342A1 EP91909510A EP91909510A EP0531342A1 EP 0531342 A1 EP0531342 A1 EP 0531342A1 EP 91909510 A EP91909510 A EP 91909510A EP 91909510 A EP91909510 A EP 91909510A EP 0531342 A1 EP0531342 A1 EP 0531342A1
Authority
EP
European Patent Office
Prior art keywords
ala
leu
phe
trp
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91909510A
Other languages
German (de)
French (fr)
Other versions
EP0531342A4 (en
Inventor
David H. Coy
Sun Hyuk Kim
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Ipsen Bioscience Inc
Original Assignee
Tulane University
Ipsen Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University, Ipsen Bioscience Inc filed Critical Tulane University
Publication of EP0531342A1 publication Critical patent/EP0531342A1/en
Publication of EP0531342A4 publication Critical patent/EP0531342A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to peptides useful for treatment of benign or malignant proliferation of tissue.
  • the amphibian peptide bombesin pGlu-Gln-Arg- Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (Anastasi et al., Experientia 22:166-167 (1971)), is closely related to the mammalian gastrin-releasing peptides (GRP), e.g., the porcine GRP, H 2 N- Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr- Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala- Val-Gly-His-Leu-Met-(NH 2 ) (McDonald et al., Biochem.
  • GRP mammalian gastrin-releasing peptides
  • Bombesin exhibits both direct and indirect effects on the gastrointestinal tract, including the release of hormones and the stimulation of pancreatic, gastric, an intestinal secretion and of intestinal mobility.
  • Gastrin and cholecystokinin (CCK) which are released by bombesin, have been shown to play a role in the maintenance of normal gastrointestinal mucosa as well a in augmenting growth of normal and neoplastic tissues.
  • Nle H 2 N-CH-C00H (norleucine)
  • R right (D) configuration
  • S left (L) configuration
  • racemate equal mix of R and S
  • 3-methyl-His methyl (CH 3 ) group on nitrogen at positions 1 or 3 of Histidine:
  • the invention features a linear or a cyclic therapeutic peptide, which includes between seven and ten amino acid residues, inclusive, and which is an analog of one of the following naturally occurring peptides which terminate at the carboxy-terminus with a Met residue: (a) litorin; (b) the ten amino acid carboxy-terminal region of mammalian GRP, neuromedin B, or neuromedin C; and (c) the ten amino acid carboxy-terminal region of amphibian bombesin, which is an analog of the formula:
  • a 2 Gly, D- or L- isomer of any of pGlu, Ala, Val, Gin, Asn, Leu, lie,
  • a 6 Sar, Gly or the D-isomer of any Ala, N-methyl-Ala, Val, Gin, Asn, Leu, lie, p-X-Phe
  • X H, F, Cl, Br, N0 2 , OH, or CH 3
  • Trp Cys, or /3-Nal
  • a 7 1-methyl-His, 3-methyl-His, His, Lys, Asp, or Glu
  • a 8 Leu, lie, Val, Nle, a-aminobutyric acid, p-X-Phe
  • each R j ⁇ and R 2 independently, is H, C 1 _ 12 alkyl, c 7 _ 10 phenylalkyl, COE j ⁇ (where E ⁇ is C 1 _ 20 alkyl, c 3 _ 20 alkenyl, C 3 - 20 aiki ⁇ y 1 - phenyl, naphthyl, or C 7 _ 10 phenylalkyl), or c ⁇ c i 2 acy1 ' and R ⁇ and R 2 are b °nded to the N-terminal amino acid of the peptide; provided that when one of R j or R 2 is COE j , the other must be H; and R 3 is H, NH 2 , C ⁇ - 12 7 - ⁇ o phenylalkyl, or C 3 _ 20 naphthylalkyl; and further provided that, if A 0 is present, A 1 cannot be pGlu; and, if A 0 or A 1 is present
  • a 3 can be bonded to A 9 to form a cyclized peptide; and provided that where A 0 is deleted and A 1 is Asp or Glu, or where A and A 1 are deleted and A is Asp or Glu, either A 1 or A 2 can be bonded with A 7 or A 8 , where A 7 or A 8 is Lys, or where A 0 is deleted and A 1 is
  • Lys or A 0 and A 1 are deleted and A 2 is Lys, either A 1 or
  • a 2 can be bonded to A 7 or A 8 , where A 7 or A 8 is Asp or Glu; and further provided that either one of A 1 or A 2 can be Cys and can be bonded through a disulfide bridge with either A 8 or A 9 , provided that either one of A 8 or A 9 can be Cys and can be bonded through a disulfide bridge with either A 1 or A 2 ; and further provided that where A 0 and A 1 are deleted and A 6 is D-Ala, A 8 -A 9 cannot be
  • R ⁇ or R 2 when either of R ⁇ or R 2 is an aliphatic, aromatic, or lipophilic group, the .in vivo activity can be long lasting, and delivery of the compounds of the invention to the target tissue can be facilitated.
  • a 1 pGlu, D-Phe, D-Ala, D-/3-Nal, D-Cpa, D-Asn, Cys, or is deleted;
  • a 2 pGlu, Asn, Gin, His, 1-methyl-His, 3-methyl-His, Cys, or is deleted;
  • a 3 Trp;
  • a 6 Sar, Gly, D-Phe, or D-Ala;
  • a 9 L-isomer of any of Met, Leu, lie, Nle, Phe, or Cys.
  • Examples of preferred peptide analogs are: pGlu-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH 2 ; D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH 2 ;
  • the invention also features a linear or a cyclic therapeutic peptide, which includes between seven and ten amino acid residues, inclusive, and which is an analog of one of the following naturally occurring peptides which terminate at the carboxy-terminus with a Met residue: (a) litorin; (b) the ten amino acid carboxy-terminal region of mammalian GRP, neuromedin B, or neuromedin C; and (c) the ten amino acid carboxy-terminal region of amphibian bombesin, and the analog is an agonist of one of these naturally occurring peptides.
  • the analog may be an agonist or a partial agonist of the naturally occurring biologically active peptide; preferably, the analog is at least 25%, more preferably 50% or 75%, homologous with a region of the naturally occurring peptide.
  • an "agonist” mimics or enhances the biological effect of the natural peptide on its target cell and a "partial agonist” mimics or enhances the biological effect of the natural peptide, but to a lesser extent than an agonist.
  • Biological effect is measured by the effect of the natural peptide in one of two systems: an in vitro pancreatic amylase release assay and an in vitro 3T3 fibroblast cell division system, both of which are described in European Patent Application 88308916.6, hereby incorporated by reference.
  • An agonist will stimulate the effect of the natural peptide on either amylase release from pancreatic cells or fibroblast cell division by 100%, whereas a partial agonist will have a lesser stimulatory effect, i.e., ranging between 0-99%.
  • Peptides of the invention are useful for treating non-malignant proliferative disease in a human patient, e.g., the proliferation of smooth muscle.
  • Peptides of the invention are also useful for treating cancer in a human patient, particularly for the treatment of prostatic, colon, breast, pancreatic, or lung cancer.
  • peptides of the invention may be used to suppress appetite, to stimulate pancreatic secretion, or to suppress a craving for alcohol.
  • Analogs of the invention can be provided in the form of pharmaceutically acceptable salts.
  • preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluene sulfonic, trifluoroacetic, or pa oic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as the hydrohalic acids,e.g., hydrochloric acid, sulfuric acid or phosphoric acid.
  • hydrohalic acids e.g., hydrochloric acid, sulfuric acid or phosphoric acid.
  • Fig. 1 is the amino acid sequences of naturally occurring peptides of which peptides of the invention are analogs. We now describe the structure, synthesis, and use of the preferred embodiments of the invention. Structure
  • Peptides of the invention are derived from one of the sequences shown in Fig. 1, which represent the sequences, or portions thereof, of naturally-occurring peptides. Bombesin, neuromedin B, neuromedin C, litorin, and GRP analogs of the invention are described in Coy et al., U.S. Patent Application Serial No. 502,438, filed March 30, 1990, which is a continuation-in-part of U.S. Patent Application Serial No. 397,169, filed August 21, 1989, which is a continuation-in-part of U.S. Patent Application Serial No. 376,555, filed July 7, 1989, and U.S. Patent Application Serial Number 394,727, filed August 16, 1989, both of which are continuation-in-parts of U.S.
  • D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH 2 follows.
  • Other bombesin or GRP agonists can be prepared by making appropriate modifications of the following synthetic method. 1) Incorporation of alpha-t-butoxycarbonyl (BOC)- leucine on 4-methyl benzhydrylamine.
  • 4-methyl benzhydryla ine-polystyrene resin (Bachem, Inc.) (0.72 meq/g) in the chloride ion form is placed in the reaction vessel of an ACT200 peptide synthesizer (Advanced Chem Tech, Inc.) programmed to perform the following reaction cycle: (a) methylene chloride; (b) 10% triethylamine in chloroform; (c) methylene chloride; and (d) dimethylformide.
  • the neutralized resin is mixed with alpha-t-butoxycarbonyl (BOC)-leucine and diisopropylcarbodiimide (3 molar eq each) in methylene chlrodie for 1 hour.
  • the resulting amino acid resin is washed on the synthesizer with dimethylformamide and treated with 5% acetic anhydride in dimethylformamide for 5 min. Then it is washed with dimethylformamide and methylene chloride. 2) Couplings of the remaining amino acids.
  • the peptide synthesizer is programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid (TFA) in methylene chloride (2 times for 5 and 25 min. each) ; (c) methylene chloride; (d) isopropyl alcohol; (e) 10% triethylamine in chloroform; and (f) methylene chloride.
  • TFA trifluoroacetic acid
  • the peptide resin described above (1.41 g) is mixed with anisole (5 ml) , dithioerythreitol (50mg) , and anhydrous hydrogen fluoride (25 ml) at 0°c for one hour. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen, and the residue is washed in ether. Crude peptide is dissolved in 100ml of 4M acetic acid and the solution is then evaporated under reduced pressure. The crude peptide is dissolved in minimum volume of methanol/water and triturated with ethyl acetate. The triturated peptide is applied to a column (9.4mm I.D.
  • Peptides of the invention may be cyclized as follows.
  • Crude peptide acid obtained from peptide-resin ester by HF cleavage is dissolved in DMF (0.1%-1% concentration), treaed with condensing agent (e.g., BOP reagent, DEPC, DPPA, or any other condensing agent) followed by base (e.g., triethylamine, diisopropylethylamine) at room temperature for 1-3 days. Solvent is removed in vacuum to dryness. The residue is purified by HPLC, according to conventional procedures.
  • condensing agent e.g., BOP reagent, DEPC, DPPA, or any other condensing agent
  • base e.g., triethylamine, diisopropylethylamine
  • Analogs of the invention may prevent or inhibit the growth of cancer cells, or may prevent the proliferation of non-malignant tissue, by acting as agonists or partial agonists; i.e., the analog may fully or partially mimic or enhance the biological effect of the natural peptide on a target cell.
  • One possible mechanism of analog inhibition of growth of cancer cells is suggested in Bunn et al. (1990, Proc. Nat. Aca. Sci. 87:2162) , in which calcium ion flux was measured in CHO cells after administration of one or more neuropeptides. Bunn et al.
  • Analogs of the invention are useful for treating colon, prostatic, breast, pancreatic, or lung cancer, for preventing the proliferation of smooth muscle, to suppress appetite, to stimulate pancreatic secretion, or to suppress a craving for alcohol.
  • Analogs of the invention are administered to a mammal, particularly a human, in one of the traditional modes (e.g., orally, parenterally, transdermally, or trans ucosally) , in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels and liposomes, or rectally (e.g., by suppository or enema) .
  • the analogs can be administered to a human patient in a dosage of 0.25 mg/kg/day to 5 mg/kg/day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptide thérapeutique comprenant entre sept et dix restes d'acides aminés. De plus, le peptide est un analogue des peptides suivants qui se produisent naturellement et se terminent à la terminaison carboxy avec un reste Met: (a) litorine; (b) la région de GRP mammifère à terminaison carboxy de dix acides aminés, neuromédine B, ou neuromédine C; et (c) la région de bombésine amphibie à terminaison carboxy de dix acides aminés, l'analogue susmentionné étant un antagoniste d'un des peptides qui se produisent naturellement.A therapeutic peptide comprising between seven and ten amino acid residues. In addition, the peptide is an analogue of the following peptides which occur naturally and terminate at the carboxy terminus with a Met residue: (a) litorin; (b) the mammalian GRP region with ten carboxy-terminated amino acids, neuromedin B, or neuromedin C; and (c) the carboxy-terminated amphibious bombesin region of ten amino acids, the aforementioned analog being an antagonist of one of the naturally occurring peptides.

Description

CYCLIZED AND LINEAR THERAPEUTIC PEPTIDES Background of the Invention This invention relates to peptides useful for treatment of benign or malignant proliferation of tissue.
The amphibian peptide bombesin, pGlu-Gln-Arg- Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (Anastasi et al., Experientia 22:166-167 (1971)), is closely related to the mammalian gastrin-releasing peptides (GRP), e.g., the porcine GRP, H2N- Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr- Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala- Val-Gly-His-Leu-Met-(NH2) (McDonald et al., Biochem. Biophys. Res. Commun. ϊH):227-233 (1979)) and human GRP, H2N-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-M e t-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met (NH2) . Bombesin has been found to be a growth factor for a number of human cancer cell lines, including small-cell lung carcinoma (SCLC) , and has been detected in human breast and prostate cancer (Haveman et al., eds. Recent Results in Cancer Research - Peptide Hormones in Lung Cancer. Springer-Verlag, New York:1986). A number of these cancers are known to secrete peptide hormones related to GRP or bombesin. Consequently, antagonists to bombesin have been proposed as agents for the treatment of these cancers.
Cuttitta et al. demonstrated that a specific monoclonal antibody to bombesin inhibited in vivo the growth of a human small-cell lung cancer cell line xenografted to nude mice (Cuttitta et al., Cancer Survey 4.:707-727 (1985)). In 3T3 murine fibroblasts which are responsive to the itotic effect of bombesin, Zachary and Rozengurt observed that a substance P antagonist (Spantide) acted as a bombesin antagonist (Zachary et al. , Proc. Natl. Acad. Sci . (USA) , 82.: 7616-7620 (1985) ) . Heinz-Erian et al. replaced His at position 12 in bombesin with D-Phe and observed bombesin antagonist activity in dispersed acini from guinea pig pancreas (Heinz-Erian et al., Am. J. of Physiol. 252:G439-G442 (1987)). Rivier reported work directed toward restricting the conformational freedom of the bioactive C-terminal decapeptide of bombesin by incorporating intramolecular disulfide bridges; however, Rivier mentioned that, so far, bombesin analogs with this modification fail to exhibit any antagonist activity (Rivier et al. , "Competitive Antagonists of Peptide Hormones," in Abstracts of the International Symposium on Bombesin-Like Peptides in Health and Disease, Rome, Italy (October, 1987) . Bombesin exhibits both direct and indirect effects on the gastrointestinal tract, including the release of hormones and the stimulation of pancreatic, gastric, an intestinal secretion and of intestinal mobility. Gastrin and cholecystokinin (CCK) which are released by bombesin, have been shown to play a role in the maintenance of normal gastrointestinal mucosa as well a in augmenting growth of normal and neoplastic tissues. The growth of xenografted human colon and stomach carcinomas in nude mice has been stimulated by the administration of gastrin and later inhibited with the addition of secretin (Tanake et al., 1986, Tokaku J. Exp. Med. 148:459) and the growth of MC-26 murine colon carcinoma, which possesses gastrin receptors is stimulated by pentagastrin (Winsett et al., 1980, Surgery 99:302, and inhibited by proglumide, a gastrin-receptor antagonist, Beauchamp et al., 1985, Ann. Surg. 202:303. Bombesin has been found to act concurrently as both a trophic agent for normal host pancreas and a growth inhibitory agent in xenografted human pancreatic tumor tissue, Alexander et al., 1988, Pancreas 3:247. Abbreviations (uncommon) : cyclohexyl-Ala = CHx-Ala (cyclohexyl alanine) H2, C identifying group
NH2~CH—C02H; pGlu = H2C CH-COOH (pyroglutamic acid) ;
H2C NH C O
Nle = H2N-CH-C00H (norleucine)
(CH2)3-CH3 Pal = 3-pyridyl-alanine D-Cpa = D-para-chloro-phenylalanine HyPro = hydroxyproline Nal = naphthylalanine Sar = sarcosine
F5-Phe = penta-fluoro-phenylalanine
R = right (D) configuration; S = left (L) configuration; racemate = equal mix of R and S
1-methyl-His; 3-methyl-His = methyl (CH3) group on nitrogen at positions 1 or 3 of Histidine:
Summary of the Invention The invention features a linear or a cyclic therapeutic peptide, which includes between seven and ten amino acid residues, inclusive, and which is an analog of one of the following naturally occurring peptides which terminate at the carboxy-terminus with a Met residue: (a) litorin; (b) the ten amino acid carboxy-terminal region of mammalian GRP, neuromedin B, or neuromedin C; and (c) the ten amino acid carboxy-terminal region of amphibian bombesin, which is an analog of the formula:
Rι
A0_A1_A2_A3_A _A5_A6_A7.A8_A9_R3
R2
wherein A0 = Gly, D- or L- isomer of any of pGlu, Nle, a-aminobutyric acid, Ala, Val, Gin, Asn, Leu, lie, p-X-Phe (where X = H, F, Cl, Br, N02, OH, CH3) , Trp, or j8-Nal, or is deleted; A1 = the D- or L-isomer of any of pGlu, Nle, a-aminobutyric acid, Ala, Val, Gin, Asn, Leu, lie, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Asp, Glu, F5-Phe, Trp, j8-Nal, Cys, Lys, or is deleted; A2 = Gly, D- or L- isomer of any of pGlu, Ala, Val, Gin, Asn, Leu, lie, p-X-Phe (where X = H, F, Cl,
Br, N02, OH, or CH3) , Trp, jS-Nal, Asp, Glu, His, 1-methyl-His 3-methyl-His, Cys, Lys, or is deleted; A = the D- or L-isomer of any of p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , j8-Nal, or Trp;
A4 = Ala, Val, Gin, Asn, Gly, Leu, lie, Nle, a-aminobutyric acid, p-X-phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, or j8-Nal; A5 = Gin, Asn, Gly, Ala, Leu, lie, Nle, a-aminobutyric acid, Val, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Thr, or /3-Nal; A6 = Sar, Gly or the D-isomer of any Ala, N-methyl-Ala, Val, Gin, Asn, Leu, lie, p-X-Phe
(where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Cys, or /3-Nal; A7 = 1-methyl-His, 3-methyl-His, His, Lys, Asp, or Glu; A8 = Leu, lie, Val, Nle, a-aminobutyric acid, p-X-Phe
(where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Thr, 3-Nal, Lys, Asp, Glu, CHx-Ala, or Cys; A9 = L-isomer of any of Met, Met-oxide, Leu, lie, Nle, a-aminobutyric acid, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, /3-Nal, CHx-Ala, or
Cys; each Rj^ and R2, independently, is H, C1_12 alkyl, c 7_10 phenylalkyl, COEj^ (where Eχ is C1_20 alkyl, c 3_20 alkenyl, C 3-20 aikiπy1- phenyl, naphthyl, or C7_10 phenylalkyl), or cι~ci2 acy1' and Rι and R 2 are b°nded to the N-terminal amino acid of the peptide; provided that when one of Rj or R2 is COEj, the other must be H; and R3 is H, NH2, Cι-12 7-ιo phenylalkyl, or C3_20 naphthylalkyl; and further provided that, if A0 is present, A1 cannot be pGlu; and, if A0 or A1 is present, A2 cannot be pGlu; and further provided that, when A is deleted and A is pGlu, R must be H and R2 must be the portion of Glu that forms the imine ring in pGlu; and further provided that, where A0 is deleted and A1 is not pGlu, A1 may be bonded to A9, or where A0 and A1 are deleted and A2 is not pGlu, A2 may be bonded to A , or where A0, A1 and A are deleted. A3 can be bonded to A9 to form a cyclized peptide; and provided that where A0 is deleted and A1 is Asp or Glu, or where A and A1 are deleted and A is Asp or Glu, either A1 or A2 can be bonded with A7 or A8, where A7 or A8 is Lys, or where A0 is deleted and A1 is
Lys or A0 and A1 are deleted and A2 is Lys, either A1 or
A2 can be bonded to A7 or A8, where A7 or A8 is Asp or Glu; and further provided that either one of A1 or A2 can be Cys and can be bonded through a disulfide bridge with either A8 or A9, provided that either one of A8 or A9 can be Cys and can be bonded through a disulfide bridge with either A1 or A2; and further provided that where A0 and A1 are deleted and A6 is D-Ala, A8-A9 cannot be
Leu-Met-NH2; or a pharmaceutically acceptable salt thereof.
In the generic formula given above, when either of Rχ or R2 is an aliphatic, aromatic, or lipophilic group, the .in vivo activity can be long lasting, and delivery of the compounds of the invention to the target tissue can be facilitated.
More preferably, the analog of the generic formula above is of the formula: A0 = pGlu, Gly, D-Phe, or is deleted;
A1 = pGlu, D-Phe, D-Ala, D-/3-Nal, D-Cpa, D-Asn, Cys, or is deleted;
A2 = pGlu, Asn, Gin, His, 1-methyl-His, 3-methyl-His, Cys, or is deleted; A3 = Trp;
A4 = Ala;
A5 = Val;
A6 = Sar, Gly, D-Phe, or D-Ala;
A7 = His; A8 = Leu, Phe, Chx-Ala, or Cys;
A9 = L-isomer of any of Met, Leu, lie, Nle, Phe, or Cys.
Examples of preferred peptide analogs are: pGlu-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2; D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 ;
D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 ;
D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2 ;
D-Cpa-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2 ; pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Met-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-Gly-His-CHx-Ala-Leu-NH2 ;
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Nle-NH2 ;
D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Nle-NH2 ;
D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Nle-NH2 ;
Ac-His-Trp-Ala-Val-D-Ala-His-Leu
-Leu-NH,
cyclo-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu;
D-Cys-Asn-Trp-Ala-Val-Gly-His-Leu-Cys-NH2 ;
cyclo-His-Trp-Ala-Val-Gly-His-Leu-Met;
Cys-Trp-Ala-Val-Gly-His-Leu-Cys-NH2 ;
cyclo-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met;
cyclo-D-Phe-His-Trp-Ala-Val-Gly-His-Leu-Met;
and cyclo-Trp-Ala-Val-Gly-His-Leu-Met; Modification of a natural amino acid or substitution of a synthetic amino acid, examples of which are (but are not limited to) pGlu, Nle, Pal, D-Cpa, Met-oxide, Nal, Sar, 1-methyl-His, or 3-methyl-His, at one or more of positions A0, A1, A6, or A9 of an analog, or cyclization of the analog result in enhanced stability; i.e., protection of the amino terminus from exopeptidase degradation and of the internal portion of the peptide from endopeptidase degradation. The carboxy-terminal dipeptide sequence of some analogs of the invention corresponds to the natural C-terminal sequence of bombesin or bombesin-related analogs.
The invention also features a linear or a cyclic therapeutic peptide, which includes between seven and ten amino acid residues, inclusive, and which is an analog of one of the following naturally occurring peptides which terminate at the carboxy-terminus with a Met residue: (a) litorin; (b) the ten amino acid carboxy-terminal region of mammalian GRP, neuromedin B, or neuromedin C; and (c) the ten amino acid carboxy-terminal region of amphibian bombesin, and the analog is an agonist of one of these naturally occurring peptides. In preferred embodiments, the analog may be an agonist or a partial agonist of the naturally occurring biologically active peptide; preferably, the analog is at least 25%, more preferably 50% or 75%, homologous with a region of the naturally occurring peptide. As used herein, an "agonist" mimics or enhances the biological effect of the natural peptide on its target cell and a "partial agonist" mimics or enhances the biological effect of the natural peptide, but to a lesser extent than an agonist. Biological effect, as used herein, is measured by the effect of the natural peptide in one of two systems: an in vitro pancreatic amylase release assay and an in vitro 3T3 fibroblast cell division system, both of which are described in European Patent Application 88308916.6, hereby incorporated by reference. An agonist will stimulate the effect of the natural peptide on either amylase release from pancreatic cells or fibroblast cell division by 100%, whereas a partial agonist will have a lesser stimulatory effect, i.e., ranging between 0-99%.
Peptides of the invention are useful for treating non-malignant proliferative disease in a human patient, e.g., the proliferation of smooth muscle. Peptides of the invention are also useful for treating cancer in a human patient, particularly for the treatment of prostatic, colon, breast, pancreatic, or lung cancer. In addition, peptides of the invention may be used to suppress appetite, to stimulate pancreatic secretion, or to suppress a craving for alcohol.
Analogs of the invention can be provided in the form of pharmaceutically acceptable salts. Examples of preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluene sulfonic, trifluoroacetic, or pa oic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as the hydrohalic acids,e.g., hydrochloric acid, sulfuric acid or phosphoric acid.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Description of the Preferred Embodiments Before describing preferred embodiments of the invention, the drawing will briefly be described. Drawing
Fig. 1 is the amino acid sequences of naturally occurring peptides of which peptides of the invention are analogs. We now describe the structure, synthesis, and use of the preferred embodiments of the invention. Structure
Peptides of the invention are derived from one of the sequences shown in Fig. 1, which represent the sequences, or portions thereof, of naturally-occurring peptides. Bombesin, neuromedin B, neuromedin C, litorin, and GRP analogs of the invention are described in Coy et al., U.S. Patent Application Serial No. 502,438, filed March 30, 1990, which is a continuation-in-part of U.S. Patent Application Serial No. 397,169, filed August 21, 1989, which is a continuation-in-part of U.S. Patent Application Serial No. 376,555, filed July 7, 1989, and U.S. Patent Application Serial Number 394,727, filed August 16, 1989, both of which are continuation-in-parts of U.S. Patent Application Serial No. 317,941, filed March 2, 1989, which is a continuation-in-part of U.S. Patent Application Serial Number 282,328, filed December 9, 1988, which in turn is a continuation-in-part of U.S. Patent Application Serial No. 257,998, filed October 14, 1988, which in turn is a continuation-in-part of U.S. Patent Application Serial No. 248,771, filed September 23, 1988, which in turn is a continuation-in-part of Coy et al., U.S. Patent Application Serial No. 207,759, filed June 16, 1988, which in turn is a continuation-in-part of Coy et al., U.S. Patent Application Serial No. 204,171, filed June 8, 1988, which in turn is a continuation-in-part of Coy et al., U.S. Patent Application Serial No. 173,311, filed March 25, 1988, which in turn is a continuation-in-part of Coy et al. U.S. Patent Application Serial No. 100,571, filed September 24, 1987; all of which are assigned to the same assignee and hereby incorporated by reference; or as described in Zachary et al., Proc. Nat. Aca. Sci. 82:7616, 1985; Heimbrook et al., "Synthetic Peptides: Approaches to Biological Problems", UCLA Symposium on Mol. and Cell. Biol. New Series, Vol. 86, ed. Tarn and Kaiser; Heinz-Erian et al., Am. J. Physiol. G439, 1986; Martinez et al., J. Med. Che . 28:1874, 1985; Gargosky et al., Biochem. J. 247:427, 1987; Dubreuil et al., Drug Design and Delivery, Vol 2:49, Harwood Academic Publishers, GB, 1987; Heikkila et al., J. Biol. Chem. 262:16456, 1987; Caranikas et al., J. Med. Chem. 25:1313, 1982; Saeed et al., 1989, Peptides 10:597; Rosell et al., Trends in Pharmacological Sciences 3:211, 1982; Lundberg et al., Proc. Nat. Aca. Sci. 80:1120, 1983; Engberg et al., Nature 293:222, 1984; Mizrahi et al.. Euro. J. Pharma. 82:101, 1982; Leander et al., Nature 294:467, 1981; Woll et al., Biochem. Biophys. Res. Comm. 155:359, 1988; Rivier et al. , Biochem.
17:1766, 1978; Cuttitta et al., Cancer Surveys 4:707, 1985; Aumelas et al., Int. J. Peptide Res. 30:596, 1987; all of which are hereby incorporated by reference. Synthesis of Analogs The synthesis of the bombesin agonist, BIM-26187,
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 follows. Other bombesin or GRP agonists can be prepared by making appropriate modifications of the following synthetic method. 1) Incorporation of alpha-t-butoxycarbonyl (BOC)- leucine on 4-methyl benzhydrylamine.
4-methyl benzhydryla ine-polystyrene resin (Bachem, Inc.) (0.72 meq/g) in the chloride ion form is placed in the reaction vessel of an ACT200 peptide synthesizer (Advanced Chem Tech, Inc.) programmed to perform the following reaction cycle: (a) methylene chloride; (b) 10% triethylamine in chloroform; (c) methylene chloride; and (d) dimethylformide. The neutralized resin is mixed with alpha-t-butoxycarbonyl (BOC)-leucine and diisopropylcarbodiimide (3 molar eq each) in methylene chlrodie for 1 hour. The resulting amino acid resin is washed on the synthesizer with dimethylformamide and treated with 5% acetic anhydride in dimethylformamide for 5 min. Then it is washed with dimethylformamide and methylene chloride. 2) Couplings of the remaining amino acids.
The peptide synthesizer is programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid (TFA) in methylene chloride (2 times for 5 and 25 min. each) ; (c) methylene chloride; (d) isopropyl alcohol; (e) 10% triethylamine in chloroform; and (f) methylene chloride.
The following amino acids (3 molar eq.) are then coupled successively by the same procedure: BOC-Leu, BOC-His (tosyl) , BOC-Gly, BOC-Val, BOC-Ala, BOC-Trp, BOC-Gln (coupled in the presence of 1 eq. hydroxybenzotriazole) , BOC-D-Phe (coupled in the presence of 1 eq. hydroxybenzotriazole) . The completed resin is then washed with methanol and air dried.
The peptide resin described above (1.41 g) is mixed with anisole (5 ml) , dithioerythreitol (50mg) , and anhydrous hydrogen fluoride (25 ml) at 0°c for one hour. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen, and the residue is washed in ether. Crude peptide is dissolved in 100ml of 4M acetic acid and the solution is then evaporated under reduced pressure. The crude peptide is dissolved in minimum volume of methanol/water and triturated with ethyl acetate. The triturated peptide is applied to a column (9.4mm I.D. x 50 cm) of octadecylcilane-silica (Whatman Partisil 10 ODS - 2M9) . The peptide is eluted with a linear gradient of 20-80% of 50/50 0.1% TFA/Acetronitrile i 0.1% TFA in water. Fractions are examined by analytical high performance liquid chromatography and appropriate fractions are evaporated to a small volume, which is further lyophilized, gives 65mg of the product as a colorless powder.
Other compounds including D-Cpa1, CHx-Ala8, or Nle 9 can be prepared as above.
Peptides of the invention may be cyclized as follows.
Crude peptide acid obtained from peptide-resin ester by HF cleavage is dissolved in DMF (0.1%-1% concentration), treaed with condensing agent (e.g., BOP reagent, DEPC, DPPA, or any other condensing agent) followed by base (e.g., triethylamine, diisopropylethylamine) at room temperature for 1-3 days. Solvent is removed in vacuum to dryness. The residue is purified by HPLC, according to conventional procedures. The cyclization of, for example, cyclo[D-Phe1, Leu8, Leu9]Litorin, in which D-Phe1 is covalently linked to Leu9, is accomplished according to the above procedure using Benzotriazol-1-yloxytris(dimethylamine)phosphonium hexafluorophosphate a the BOP reagent, diethylcyanophosphonate as the DEPC reagent, and diphenylphosphoryalazide as the DPPA reagent. Mechanism of Action
Analogs of the invention may prevent or inhibit the growth of cancer cells, or may prevent the proliferation of non-malignant tissue, by acting as agonists or partial agonists; i.e., the analog may fully or partially mimic or enhance the biological effect of the natural peptide on a target cell. One possible mechanism of analog inhibition of growth of cancer cells is suggested in Bunn et al. (1990, Proc. Nat. Aca. Sci. 87:2162) , in which calcium ion flux was measured in CHO cells after administration of one or more neuropeptides. Bunn et al. observed a desensitization of cells to the neuropeptide after administration of the second dose, i.e., after administration of the first dose and the return of calcium concentration to resting values, administration of a second dose of an identical peptide resulted in no calcium flux. However, when the second dose was administered using a different peptide, a new calcium flux occurred. Thus different peptides may trigger different calcium flux pathways. The results of Bunn et al. show that desensitization to the neuropeptide may occur both in cancerous and normal tissue, thus suggesting that an agonist may suppress growth in a tumor cell by a similar mechanism. Use
Analogs of the invention are useful for treating colon, prostatic, breast, pancreatic, or lung cancer, for preventing the proliferation of smooth muscle, to suppress appetite, to stimulate pancreatic secretion, or to suppress a craving for alcohol. Analogs of the invention are administered to a mammal, particularly a human, in one of the traditional modes (e.g., orally, parenterally, transdermally, or trans ucosally) , in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels and liposomes, or rectally (e.g., by suppository or enema) . The analogs can be administered to a human patient in a dosage of 0.25 mg/kg/day to 5 mg/kg/day.
Other embodiments are within the following claims.

Claims

Claims
1. A therapeutic peptide comprising between seven and ten amino acid residues, inclusive, said peptide being an analog of one of the following naturally occurring peptides which terminate at the carboxy-terminus with a Met residue: (a) litorin; (b) the ten amino acid carboxy-terminal region of mammalian GRP, neuromedin B, or neuromedin C; and (c) the ten amino acid carboxy-terminal region of amphibian bombesin, said analog being of the formula: Rχ A°-A1-A2-A3-A -A5-A6-A7-A8-A9-R3 R2
wherein A = Gly, D- or L- isomer of any of pGlu, Nle, a-aminobutyric acid, Ala, Val, Gin, Asn, Leu, He, p-X-Phe (where X = H, F, Cl, Br, N02, OH, CH3) , Trp, or 3-Nal, or is deleted; A1 = the D- or L-isomer of any of pGlu, Nle, a-aminobutyric acid, Ala, Val, Gin, Asn, Leu, He, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Asp, Glu, F5-Phe, Trp, /3-Nal, Cys, Lys, or is deleted; A2 = Gly, D- or L- isomer of any of pGlu, Ala, Val, Gin, Asn, Leu, He, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, /3-Nal, Asp, Glu, His, 1-methyl-His 3-methyl-His, Cys, Lys, or is deleted; A3 = the D- or L-isomer of any of p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , /3-Nal, or Trp; A4 = Ala, Val, Gin, Asn, Gly, Leu, He, Nle, a-aminobutyric acid, p-X-phe (where X = H, F, Cl, Br, N02, OH, or CH3), Trp, or /3-Nal; A5 = Gin, Asn, Gly, Ala, Leu, He, Nle, a-aminobutyric acid, Val, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Thr, or /3-Nal; A6 = Sar, Gly or the D-isomer of any Ala, N-methyl-Ala, Val, Gin, Asn, Leu, He, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Cys, or /3-Nal; A7 = 1-methyl-His, 3-methyl-His, His, Lys, Asp, or Glu; A = Leu, He, Val, Nle, a-aminobutyric acid, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, Thr, 3-Nal, Lys, Asp, Glu, CHx-Ala, or Cys; A9 = L-isomer of any of Met, Met-oxide, Leu, He, Nle, a-aminobutyric acid, p-X-Phe (where X = H, F, Cl, Br, N02, OH, or CH3) , Trp, /3-Nal, CHx-Ala, or Cys; each Rχ and R2, independently, is H, Cj_12 alkyl, C?_10 phenylalkyl, COE^^ (where E^^ is C1_20 alkyl, C3_20 alkenyl, c 3_20 alkinyl, phenyl, naphthyl, or C7_10 phenylalkyl) , or cι~ci2 acy!' and Rι and R 2 are bonded to the N-terminal amino acid of the peptide; provided that when one of Rχ or R2 is COEj^, the other must be H; and R3 is H, NH2, C1-12 alkyl, C?_10 phenylalkyl, or C3_20 naphthylalkyl; and further provided that, if A is present, A cannot be pGlu; and, if A or A1 is present, A2 cannot be pGlu; and further provided that, when A0 is deleted and A1 is pGlu, Rχ must be H and R2 must be the portion of Glu that forms the imine ring in pGlu; and further provided that, where A is deleted and A1 is not pGlu, A1 may be bonded to A , or where A and A1 are deleted and A is not pGlu, A2 may be bonded to A9, or where A0, A1 and A2 are deleted. A3 may be bonded to A9; and provided that where A0 is deleted and A1 is Asp or Glu, or where A0 and A1 are deleted and A2 is Asp or Glu, either A1 or A2 can be bonded with A7 or A8, where A7 or A8 is Lys, or where A0 is deleted and A1 is Lys or A and A1 are deleted and A2 is Lys, either A1 or A can be bonded to A7 or A8, where A7 or A8 is Asp or Glu; and further provided that either one of A1 or A2 can be Cys and can be bonded through a disulfide bridge with either A8 or A9, provided that either one of A8 or A9 can be Cys and can be bonded through a disulfide bridge with either A1 or A2; and further provided that where A0 and A1 are deleted and A6 is D-Ala, A8-A9 cannot be Leu-Met-NH2; or a pharmaceutically acceptable salt thereof.
2. The therapeutic peptide of claim 1, comprising the formula: A0 = pGlu, Gly, D-Phe, or is deleted; A1 = pGlu, D-Phe, D-Ala, D-/3-Nal, D-Cpa, D-Asn, Cys, or is deleted; A2 = pGlu, Asn, Gin, His, 1-methyl-His, 3-methyl-His, Cys, or is deleted; A3 = Trp; A4 = Ala; A5 = Val; A6 = Sar, Gly, D-Phe, or D-Ala; A7 = His; A8 = Leu, Phe, Chx-Ala, or Cys; A9 = L-isomer of any of Met, Leu, He, Nle, Phe, or Cys.
3. The therapeutic peptide of claim 2, comprising the amino acid formula: pGlu-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2.
4. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2.
5. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.
6. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.
7. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2.
8. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Leu-NH2.
9. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2.
10. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Cpa-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2.
11. The therapeutic peptide of claim 2, comprising the amino acid formula: pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2.
12. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2.
13. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Met-NH2.
14. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Leu-NH2.
15. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2.
16. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Nle-NH2.
17. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Nle-NH2.
18. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Nle-NH2.
19. A therapeutic peptide comprising the amino acid formula: D-p-Cl-Phe-Gln-Trp-Ala-Val-Gly-His-Leuc[CH2NH]Phe-NH2.
20. A therapeutic peptide comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-proplyamide.
21. The therapeutic peptide of claim 2, comprising the amino acid formula: Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Leu-NH2.
22. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Phe-Gln-Trp-Ala-Val-Gly-His-CHx-Ala-Leu-NH2.
23. The therapeutic peptide of claim 2, comprising the amino acid formula: cyclo-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu.
24. The therapeutic peptide of claim 2, comprising the amino acid formula: D-Cys-Asn-Trp-Ala-Val-Gly-His-Leu-Cys-NH2.
25. The therapeutic peptide of claim 2, comprising the amino acid formula: cyclo-His-Trp-Ala-Val-Gly-His-Leu-Met.
26. The therapeutic peptide of claim 2, comprising the amino acid formula: Cys-Trp-Ala-Val-Gly-His-Leu-Cys-NH2.
27. The therapeutic peptide of claim 2, comprising the amino acid formula: cyclo-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met.
28. The therapeutic peptide of claim 2, comprising the amino acid formula: cyclo-D-Phe-His-Trp-Ala-Val-Gly-His-Leu-Met.
29. The therapeutic peptide of claim 2, comprising the amino acid formula: cyclo-Trp-Ala-Val-Gly-His-Leu-Met. 1 30. A therapeutic peptide comprising 2,between seven and ten amino acid residues, inclusive, 3said peptide being an analog of one of the following 4;naturally occurring peptides which terminate at the Scarboxy-terminus with a Met residue: (a) litorin; (b) 6the ten amino acid carboxy-terminal region of 7mammalian GRP, neuromedin B, or neuromedin C; and (c) 8the ten amino acid carboxy-terminal region of 9amphibian bombesin, said analog being an agonist of lOone of said naturally occurring peptides.
1 31. The therapeutic peptide of claim 30, 2wherein said peptide is a partial agonist of said 3naturally occurring biologically active peptide.
1 32. The therapeutic peptide of claim 30,
2said analog being at least 25% homologous with said 3naturally occurring peptide.
1 33. The therapeutic peptide of claim 32, 26aid analog being at least 50% homologous with said 3naturally occurring peptide.
EP91909510A 1990-05-09 1991-05-09 Cyclized and linear therapeutic peptides Withdrawn EP0531342A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52022690A 1990-05-09 1990-05-09
US520226 1990-05-09

Publications (2)

Publication Number Publication Date
EP0531342A1 true EP0531342A1 (en) 1993-03-17
EP0531342A4 EP0531342A4 (en) 1994-04-06

Family

ID=24071694

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91909510A Withdrawn EP0531342A1 (en) 1990-05-09 1991-05-09 Cyclized and linear therapeutic peptides

Country Status (5)

Country Link
EP (1) EP0531342A1 (en)
JP (1) JPH05506862A (en)
CA (1) CA2081890A1 (en)
HU (1) HUT62604A (en)
WO (1) WO1991017181A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689834B2 (en) 2000-09-11 2004-02-10 Bayer Aktiengesellschaft Liquid sulfur-containing oligosiloxanes and their use in rubber mixtures

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5767236A (en) * 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5834433A (en) * 1990-07-26 1998-11-10 Merrell Pharmaceuticals Inc. Compounds and pharmaceutical uses of peptides of bombesin and GRP
EP0626973A1 (en) * 1992-02-07 1994-12-07 Merrell Pharmaceuticals Inc. Phenylalanine analogs of bombesin
SI0737691T1 (en) * 1995-03-13 1998-12-31 Biomeasure, Inc. Bombesin analogs
SG173223A1 (en) 2003-04-22 2011-08-29 Ipsen Pharma Sas Peptide vectors
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
KR101731655B1 (en) 2008-06-12 2017-05-11 입센 바이오이노베이션 리미티드 Suppression of cancers
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331661A (en) * 1980-10-03 1982-05-25 The Salk Institute For Biological Studies Bombesin analogs
GB2231051A (en) * 1989-05-05 1990-11-07 Erba Carlo Spa Bombesin antagonists
WO1991004040A1 (en) * 1989-09-15 1991-04-04 Biomeasure, Inc. Treatment of colon cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207311A (en) * 1977-07-18 1980-06-10 The Salk Institute For Biological Studies Peptides having analgesic and thermoregulative properties
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
GB8813356D0 (en) * 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331661A (en) * 1980-10-03 1982-05-25 The Salk Institute For Biological Studies Bombesin analogs
GB2231051A (en) * 1989-05-05 1990-11-07 Erba Carlo Spa Bombesin antagonists
WO1991004040A1 (en) * 1989-09-15 1991-04-04 Biomeasure, Inc. Treatment of colon cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. vol. 119, no. 1 , 29 February 1984 , DULUTH, MINNESOTA US pages 14 - 20 N MINAMINO ET AL. 'neuromedin C. a bombesin-like peptide identified in porcine spinal cord' *
BIOCHEMISTRY. vol. 29, no. 3 , 23 January 1990 , EASTON, PA US pages 616 - 622 L-H WANG ET AL. 'desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimititic activity in Swiss 3T3 cells' *
BR. J. PHARMACOL. vol. 55 , 1975 , BASINGSTOKE, GB page 221-227 M BROCCARDO ET AL. 'relative potency of bombesin-like peptides' *
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 265, no. 26 , 15 September 1990 , BALTIMORE, MD US pages 15695 - 15703 L-H WANG ET AL. 'des-met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists' *
See also references of WO9117181A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689834B2 (en) 2000-09-11 2004-02-10 Bayer Aktiengesellschaft Liquid sulfur-containing oligosiloxanes and their use in rubber mixtures

Also Published As

Publication number Publication date
HUT62604A (en) 1993-05-28
JPH05506862A (en) 1993-10-07
HU9203481D0 (en) 1993-01-28
WO1991017181A1 (en) 1991-11-14
EP0531342A4 (en) 1994-04-06
CA2081890A1 (en) 1991-11-10

Similar Documents

Publication Publication Date Title
EP0309297B1 (en) Therapeutic peptides
AU648037B2 (en) Therapeutic peptides
JP2919889B2 (en) Therapeutic peptides
US20030050436A1 (en) Octapeptide bombesin analogs
US5217955A (en) Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5767236A (en) Linear therapeutic peptides
NZ299913A (en) Treatment of cancer using polypeptide bombesin/GRP antagonists
US5736517A (en) Treatment of cancer with peptides
EP0531342A1 (en) Cyclized and linear therapeutic peptides
US5620959A (en) Bombesin antagonists
EP0588873B1 (en) Treatment of liver cancer
IE912671A1 (en) Peptides
EP0737691B1 (en) Bombesin analogs
EP2198878A1 (en) Polypeptide bombesin antagonists
AU703865B2 (en) Bombesin analogs
JP3743794B2 (en) Bombesin analog
RU2088592C1 (en) Therapeutic peptides or their pharmaceutically acceptable salts
AU622123C (en) Therapeutic peptides
CA2144264A1 (en) Bombesin analogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19951012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960423